ALSO NOTED: Discount on Gardasil price; Allergy shares dip on trial disappointment;and much more...

Vaccine Market

Swiss authorities have negotiated a 40 percent discount on the price of Gardasil when it's used in a recommended vaccine program for teenage girls. Report

Hanoi officials are once again distributing vaccine supplies to fight a cholera outbreak. Report

Since the approval of a vaccine against pneumococcal bacteria for young children in 2000, rates of invasive pneumococcal disease are down significantly in all age groups, while rates of IPD caused by non-vaccine strains are modestly on the rise. Release

Acambis said it has extended its ChimeriVaxTM-JE vaccine licensing agreement with Sanofi Pasteur. Story

Vaccine Research

Shares of Allergy Therapeutics dipped this week on investors' disappointment that the FDA has yet to lift a clinical hold on its hayfever vaccine trial. Trials for Pollinex Quattro were put on hold last year after adverse events were reported. Allergy says it has enough cash on hand to get through the delay. Article

ALK-Abello says that a late stage trial of its pollen vaccine Grazax demonstrated a 28 percent reduction in symptoms and a 65 percent reduction in the need for symptom relieving medication. Report

The FDA has put a clinical hold on a trial of Dynavax's hepatitis B vaccine after one of the patients contracted Wegener's granulomatosis, a disease that inflames the blood vessels. Report

Medicago announced that its H5N1 flu vaccine, made from an Indonesian strain, provided 100 percent protection in mice against a lethal challenge with live H5N1 viruses of the Vietnam strain. Release

The Ovarian Cancer Research Fund awarded a $900,000 research grant to Kunle Odunsi, MD, Department of Gynecologic Oncology, and his team at Roswell Park Cancer Institute to collaborate on developing a vaccine to unleash the power of the immune system against cancer. Release

Diamyd Medical announced that the Swedish Medical Products Agency has approved the company's application to commence Phase III studies with the therapeutic diabetes vaccine Diamyd. Release

Suggested Articles

NIH and Moderna will need a coronavirus vaccine manufacturer, and and no major pharmaceutical company has stepped up.

GlaxoSmithKline’s vaccines unit has been a bright spot for the company, but its performance doesn’t make it immune to staff cuts.

Researchers had high hopes for a HIV vaccine candidate made up of components supplied by GlaxoSmithKline and Sanofi, but it didn't work.